Sorry mate, I didn't mean to be disrespectful to PAA, what...

First 18 Last

Share
Profile

Follow
aaragon

5,067 Posts.

822

22/03/24

12:44

Post #: 73012542
Share

Originally posted by ThePig: ↑

I'm a long-term holder of PAA and have just bought in to CHM.

I believe that if you ask all 12 patients in the PAA Motor Neurone Disease trial I'm sure they will advise you otherwise. Monepantel has provided each one a life-prolonging opportunity that all are grateful to achieve and has provided their family extended valuable time with their loved ones. There has been no advancement in MND/ALS drug progression for over 20 years so this is potentially a game-changer.

Same goes with CHM. Being a first-mover could also be a game-changer for people suffering from illnesses that the Company is addressing.

We're investing in both companies to make money that's for sure, but don't forget that we're dealing with people's lives here. Just imagine if you were suffering with Glioblastoma and you were sitting next to another person and one of you was going to receive the drug and the other a placebo? 50/50 chance.

I hope that both PAA and CHM succeed in extending life to all of their patients and we make a shite load of money. That includes patients in the MND trial who have invested in PAA since they commenced the trial. I think that speaks volumes about how they're progressing on the drug!

Expand

Sorry mate, I didn't mean to be disrespectful to PAA, what they've done in the Motor Neurone Disease is epic. I was just meaning that about the price rise of PAA, CHM would go higher, in percentage. Fingers crossed that happens.

CHM Price at posting: 3.3¢ Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply